Conference
A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).
Abstract
4514
Authors
Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Yu EY; Gleave ME
Volume
30
Pagination
pp. 4514-4514
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2012
DOI
10.1200/jco.2012.30.15_suppl.4514
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X